Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.

Area of Science:

• Nanomedicine
• Neuroscience
• Drug Delivery

Background:

• The human immunodeficiency virus (HIV) establishes reservoirs in the brain, leading to neuropathology.
• The blood-brain barrier (BBB) restricts the entry of antiretroviral drugs, like efavirenz (EFV), into the brain.
• Conventional nanoparticle production methods lack precise control over particle characteristics.

Purpose of the Study:

• To develop and compare EFV-loaded PLGA NPs produced via conventional and microfluidic methods for treating HIV neuropathology.
• To enhance BBB targeting of these nanoparticles.
• To evaluate the safety and efficacy of the developed nanosystems.

Main Methods:

• Production of EFV-loaded PLGA NPs using conventional and microfluidic techniques.
• Characterization of NPs (size, polydispersity, zeta-potential, drug loading, association efficiency).
• In vitro drug release studies, BBB targeting assessment, cell viability assays, and hemolytic activity tests.

Main Results:

• Microfluidics yielded smaller NPs with higher EFV association efficiency and drug loading compared to the conventional method.
• Functionalized NPs showed effective BBB targeting and increased EFV permeability across an in vitro BBB model.
• NPs demonstrated safety for brain endothelial and neuron cells and were non-hemolytic.

Conclusions:

• Microfluidics offers superior control for producing EFV-loaded PLGA NPs for HIV neuropathology treatment.
• Targeted PLGA NPs show promise for enhanced drug delivery across the BBB.
• The developed nanosystems are safe and effective for potential therapeutic applications.